The prescription age for the government-supplied COVID-19 treatment, Lagevrio, will be raised from 60 to 70 from the 27th. 

According to the Korea Disease Control and Prevention Agency (KCDA), the three COVID-19 drugs (Paxlovid, Lagevrio, Veklury Inj) that were initially supplied by the government, were planned to be included in Korea’s national health insurance system and transitioned to a general drug status within the year. Accordingly, Paxlovid and Veklury Inj have already been granted marketing authorization in Korea and have been covered by Korea’s health insurance since the 25th of last month. 

On the other hand, Lagevrio has not completed the marketing authoriz